전신홍반루푸스의 치료

키워드

참고문헌 (52)

1. Durcan L, "Management strategies and future directions for systemic lupus erythematosus in adults", Lancet, 393, pp.2332~2343 (2019)
2. Eun Hui Bae, "Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study", The Korean Journal of Internal Medicine, 35(3), pp.652~661 (2020), 대한내과학회[DOI]
3. Mosca M, "European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies", Ann Rheum Dis, 69, pp.1269~1274 (2010)
4. Isenberg DA, "An assessment of disease flare in patients with systemic lupus erythematosus : a comparison of BILAG 2004 and the flare version of SELENA", Ann Rheum Dis, 70, pp.54~59 (2011)
5. Fanouriakis A, "2019 update of the EULAR recommendations for the management of systemic lupus erythematosus", Ann Rheum Dis, 78, pp.736~745 (2019)
6. Dörner T, "Novel paradigms in systemic lupus erythematosus", Lancet, 393, pp.2344~2358 (2019)
7. Andreoli L, "EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and", or antiphospholipid syndrome, 2017, pp.76, 476~485
8. Mok CC, "Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus : a case-control study", Ann Rheum Dis, 72, pp.659~664 (2013)
9. Gordon C, "The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults", Rheumatology(Oxford)2018;, 57, pp.e1~[DOI]
10. Buttgereit F, "Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens : current questions and tentative answers in rheumatology", Ann Rheum Dis, 61, pp.718~722 (2002)
11. Ruiz-Arruza I, "Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control : an observational study", Arthritis Care Res(Hoboken)2018;, 70, pp.582~591
12. Willis R, "Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients : data from LUMINA(LXXV), a multiethnic US cohort", Lupus, 21, pp.830~835 (2012)
13. An J, "Cutting edge : antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase-DNA interaction", J Immunol, 194, pp.4089~4093 (2015)
14. Ruiz-Irastorza G, "Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus : a systematic review", Ann Rhuem Dis, 69, pp.20~28 (2010)
15. Kuhn A, "Cutaneous lupus erythematosus : update of therapeutic options part I", J Am Acad Dermatol, 65, pp.e179~ (2011)[DOI]
16. Williams HJ, "Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus", J Rheumatol, 21, pp.1457~1462 (1994)
17. Petri M, "Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients", Curr Rheumatol Rep, 13, pp.77~80 (2011)
18. Marmor MF, "Recommendations on screening for chloroquine and hydroxychloroquine retinopathy(2016 revision)", Ophthalmology, 123, pp.1386~1394 (2016)
19. Pego-Reigosa JM, "Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus : a systematic review", Arthritis Care Res(Hoboken)2013;, 65, pp.1775~1785
20. Carneiro JR, "Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus", J Rheumatol, 26, pp.1275~1279 (1999)
21. Fortin PR, "Steroid-sparing effects of methotrexate in systemic lupus erythematosus : a double-blind, randomized, placebo-controlled trial", Arthritis Rheum, 59, pp.1796~1804 (2008)
22. Ginzler EM, "Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis", N Engl J Med, 353, pp.2219~2228 (2005)
23. Dooley MA, "Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis", N Engl J Med, 365, pp.1886~1895 (2011)
24. Ginzler EM, "Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis : findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial", Arthritis Rheum, 62, pp.211~221 (2010)
25. Blumenfeld Z, "Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases", Semin Arthritis Rheum, 41, pp.346~352 (2011)
26. Wang S, "Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis : a non-randomized prospective cohort study", Lupus, 21, pp.1025~1035 (2012)
27. Liu Z, "Multitarget therapy for induction treatment of lupus nephritis : a randomized trial", Ann Intern Med, 162, pp.18~26 (2015)
28. Lightstone L, "Lupus nephritis and pregnancy : concerns and management", Semin Nephrol, 37, pp.347~353 (2017)
29. Furie R, "A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus", Arthritis Rheum, 63, pp.3918~3930 (2011)
30. Navarra SV, "Efficacy and safety of belimumab in patients with active systemic lupus erythematosus : a randomised, placebo-controlled, phase 3trial", Lancet, 377, pp.721~731 (2011)
31. Manzi S, "Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus : combined results from two phase III trials", Ann Rheum Dis, 71, pp.1833~1838 (2012)
32. van Vollenhoven RF, "Belimumab in the treatment of systemic lupus erythematosus : high disease activity predictors of response", Ann Rheum Dis, 71, pp.1343~1349 (2012)
33. Iaccarino L, "Efficacy and safety of off-label use of rituximab in refractory lupus : data from the Italian Multicentre Registry", Clin Exp Rheumatol, 33, pp.449~456 (2015)
34. Díaz-Lagares C, "Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis : pooled data from European cohorts", Autoimmun Rev, 11, pp.357~364 (2012)
35. Olfat M, "Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus", Lupus, 24, pp.966~972 (2015)
36. Sakthiswary R, "Methotrexate in systemic lupus erythematosus : a systematic review of its efficacy", Lupus, 23, pp.225~235 (2014)
37. Vital EM, "Brief report : responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus", Arthritis Rheumatol, 67, pp.1586~1591 (2015)
38. Chasset F, "Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus : a systematic review and meta-analysis", J Am Acad Dermatol, 78, pp.342~350 (2018)[DOI]
39. Merrill JT, "Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus : the randomized, double-blind, phase II", III systemic lupus erythematosus evaluation of rituximab trial, 2010, pp.62, 222~233
40. Koh JH, "Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus", Lupus, 24, pp.210~217 (2015)
41. Levy RA, "Hydroxychloroquine(HCQ)in lupus pregnancy : double-blind and placebo-controlled study", Lupus, 10, pp.401~404 (2001)
42. Roberge S, "Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia : a systematic review and meta-analysis", Fetal Diagn Ther, 31, pp.141~146 (2012)
43. Hereng T, "Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients", Lupus, 17, pp.11~15 (2008)
44. Erkan D, "Aspirin for primary thrombosis prevention in the antiphospholipid syndrome : a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals", Arthritis Rheum, 56, pp.2382~2391 (2007)
45. Tektonidou MG, "EULAR recommendations for the management of antiphospholipid syndrome in adults", Ann Rheum Dis, 78, pp.1296~1304 (2019)
46. Iudici M, "Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus : a long-term retrospective cohort study", Rheumatology(Oxford)2016;, 55, pp.1623~1630
47. Bernatsky S, "An international cohort study of cancer in systemic lupus erythematosus", Arthritis Rheum, 52, pp.1481~1490 (2005)
48. Buckley L, "2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis", Arthritis Care Res(Hoboken)2017;, 69, pp.1095~1110
49. Danion F, "Efficacy of abatacept in systemic lupus erythematosus : a retrospective analysis of 11patients with refractory disease", Lupus, 25, pp.1440~1447 (2016)
50. Merrill JT, "Efficacy and safety of atacicept in patients with systemic lupus erythematosus : results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study", Arthritis Rheumatol, 70, pp.266~276 (2018)
51. Furie RA, "A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study", Ann Rheum Dis, 74, pp.1667~1675 (2015)
52. Rovin BH, "A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis", Kidney Int, 95, pp.219~231 (2019)

관련 논문AI추천